ibrance

Pfizer Inc. (NYSE: PFE) shares declinded Monday after the company said that a Phase 3 breast cancer treatment study — known as "PALLAS" — is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring...

Pfizer Inc. (NYSE: PFE)'s pipeline consists of multiple growth assets that may be misunderstood by Wall Street analyst and investors. The Analyst Piper Jaffray's Richard Purkiss maintains an Overweight rating on Pfizer's stock with an unchanged $54 price target. The Thesis Pfizer...

Analysts at Morgan Stanley turned bullish on Pfizer Inc. (NYSE: PFE) amid multiple catalysts and accretive M&A opportunities ahead. Analyst David Risinger upgraded Pfizer's stock from Equal-weight to Overweight with a price target boosted from $35 to $39. Ibrance Pfizer's pipeline is...

Previewing second-quarter results of Pfizer Inc. (NYSE: PFE), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to release its second-quarter results at 7 a.m. ET on Aug. 1. Analysts led by Vamil Divan expect...

Pfizer Inc. (NYSE: PFE), Amgen, Inc. (NASDAQ: AMGN) and Eli Lilly and Co (NYSE: LLY) received favorable opinions from the European Medicines Agency in response to their respective applications. Pfizer's IBRANCE® Pfizer disclosed that the European Medicines Agency (EMA)'s Committee for Medicinal...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...

The holiday season tends to make December feel like it's gone by in an instant, so many traders are already starting to gear up for the New Year. Since the Federal Reserve's upcoming policy meeting has the potential to upset markets in the coming week, many have already begun to craft their wish-...

Pfizer Inc. (NYSE: PFE) came out with better-than-expected fourth quarter earnings results on Tuesday. However, the earnings forecasts of 2015 provided by the company were way below Wall Street expectations. The company cited strengthening dollar and patent expiration as the reasons behind lower...